One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Time to Think Differently About Sarcomere-Negative Hypertrophic Cardiomyopathy
Hugh Watkins
doi : 10.1161/CIRCULATIONAHA.121.053527
Circulation. 2021;143:2415–2417
Effect of Denosumab or Alendronic Acid on the Progression of Aortic Stenosis: A Double-Blind Randomized Controlled Trial
Tania A. Pawade, Mhairi K. Doris, Rong Bing, Audrey C. White, Laura Forsyth, Emily Evans, Catriona Graham, Michelle C. Williams, Edwin J.R. van Beek, Alison Fletcher, Philip D. Adamson, Jack P.M. Andrews, Timothy R.G. Cartlidge, William S.A. Jenkins, Maaz Syed, Takeshi Fujisawa, Christophe Lucatelli, William Fraser, Stuart H. Ralston, Nicholas Boon, Bernard Prendergast, David E. Newby, Marc R. Dweck
doi : 10.1161/CIRCULATIONAHA.121.053708
Circulation. 2021;143:2418–2427
Valvular calcification is central to the pathogenesis and progression of aortic stenosis, with preclinical and observational studies suggesting that bone turnover and osteoblastic differentiation of valvular interstitial cells are important contributory mechanisms. We aimed to establish whether inhibition of these pathways with denosumab or alendronic acid could reduce disease progression in aortic stenosis.
Hearts of Stone: Calcific Aortic Stenosis and Antiresorptive Agents for Osteoporosis
Linda L. Demer, Yin Tintut
doi : 10.1161/CIRCULATIONAHA.121.054823
Circulation. 2021;143:2428–2430
Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol
Siri Lagethon Heck, Albulena Mecinaj, Anne Hansen Ree, Pavel Hoffmann, Jeanette Schulz-Menger, Morten Wang Fagerland, Berit Gravdehaug, Helge R?sj?, Kjetil Steine, Jürgen Geisler, Geeta Gulati, Torbj?rn Omland
doi : 10.1161/CIRCULATIONAHA.121.054698
Circulation. 2021;143:2431–2440
Adjuvant breast cancer therapy containing anthracyclines with or without anti–human epidermal growth factor receptor–2 antibodies and radiotherapy is associated with cancer treatment–related cardiac dysfunction. In the PRADA trial (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy), concomitant treatment with the angiotensin receptor blocker candesartan attenuated the reduction in left ventricular ejection fraction (LVEF) in women receiving treatment for breast cancer, whereas the ?-blocker metoprolol attenuated the increase in cardiac troponins. This study aimed to assess the long-term effects of candesartan and metoprolol or their combination to prevent a reduction in cardiac function and myocardial injury.
Efficacy and Safety of Using Dual Versus Monotherapy Antiplatelet Agents in Secondary Stroke Prevention: Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials
Gabriela Trifan, Philip B. Gorelick, Fernando D. Testai
doi : 10.1161/CIRCULATIONAHA.121.053782
Circulation. 2021;143:2441–2453
Dual antiplatelet treatment (DAPT) with aspirin plus clopidogrel for a limited time is recommended after minor noncardioembolic stroke.
Systems Approach to Discovery of Therapeutic Targets for Vein Graft Disease: PPAR? Pivotally Regulates Metabolism, Activation, and Heterogeneity of Macrophages and Lesion Development
Julius L. Decano, Sasha A. Singh, Cauê Gasparotto Bueno, Lang Ho Lee, Arda Halu, Sarvesh Chelvanambi, Joan T. Matamalas, Hengmin Zhang, Andrew K. Mlynarchik, Jiao Qiao, Amitabh Sharma, Shin Mukai, Jianguo Wang, Daniel G. Anderson, C. Keith Ozaki, Peter Libby, Elena Aikawa, Masanori Aikawa
doi : 10.1161/CIRCULATIONAHA.119.043724
Circulation. 2021;143:2454–2470
Vein graft failure remains a common clinical challenge. We applied a systems approach in mouse experiments to discover therapeutic targets for vein graft failure.
Integrative Multiomics Approaches for Discovery of New Drug Targets for Cardiovascular Disease
Muredach P. Reilly, Karin E. Bornfeldt
doi : 10.1161/CIRCULATIONAHA.121.054900
Circulation. 2021;143:2471–2474
Extracellular Vesicles From Epicardial Fat Facilitate Atrial Fibrillation
Olga Shaihov-Teper, Eilon Ram, Nimer Ballan, Rafael Y. Brzezinski, Nili Naftali-Shani, Rula Masoud, Tamar Ziv, Nir Lewis, Yeshai Schary, La-Paz Levin-Kotler, David Volvovitch, Elchanan M. Zuroff, Sergei Amunts, Neta Regev-Rudzki, Leonid Sternik, Ehud Raanani, Lior Gepstein, Jonathan Leor
doi : 10.1161/CIRCULATIONAHA.120.052009
Circulation. 2021;143:2475–2493
The role of epicardial fat (eFat)-derived extracellular vesicles (EVs) in the pathogenesis of atrial fibrillation (AF) has never been studied. We tested the hypothesis that eFat-EVs transmit proinflammatory, profibrotic, and proarrhythmic molecules that induce atrial myopathy and fibrillation.
Evinacumab Approval Adds a New Option for Homozygous Familial Hypercholesterolemia With a Hefty Price Tag
Bridget M. Kuehn
doi : 10.1161/CIRCULATIONAHA.121.055463
Circulation. 2021;143:2494–2496
Highlights From the Circulation Family of Journals
doi : 10.1161/CIRCULATIONAHA.121.055871
Circulation. 2021;143:2497–2501
Things Are Not Always as They Seem: Multimodality Exercise Assessment in the Evaluation of Dyspnea
Vidhu Anand, David Bradley, Robert L. Frye, Barry A. Borlaug
doi : 10.1161/CIRCULATIONAHA.121.053615
Circulation. 2021;143:2502–2507
Reduction in Kawasaki Disease After Nonpharmaceutical Interventions in the COVID-19 Era: A Nationwide Observational Study in Korea
Ji-Man Kang, Young-Eun Kim, Kyungmin Huh, Jinwook Hong, Dong Wook Kim, Min Young Kim, Se Yong Jung, Jong-Hun Kim, Jaehun Jung, Jong Gyun Ahn
doi : 10.1161/CIRCULATIONAHA.121.054785
Circulation. 2021;143:2508–2510
Letter by Sarayani et al Regarding Article, “Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque”
Amir Sarayani, Sebastian Jugl, Almut G. Winterstein
doi : 10.1161/CIRCULATIONAHA.120.052678
Circulation. 2021;143:e1031–e1032
Response to Sarayani et al Regarding Article, “Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque”
Zsofia D. Drobni, Thomas Mayrhofer, Udo Hoffmann, Tomas G. Neilan
doi : 10.1161/CIRCULATIONAHA.121.054169
Circulation. 2021;143:e1033–e1034
2020 American Heart Association and American College of Cardiology Consensus Conference on Professionalism and Ethics: A Consensus Conference Report
Ivor J. Benjamin, C. Michael Valentine, William J. Oetgen, Katherine A. Sheehan, Ralph G. Brindis, William H. Roach Jr, Robert A. Harrington, Glenn N. Levine, Rita F. Redberg, Bernadette M. Broccolo, Adrian F. Hernandez, Pamela S. Douglas, Ileana L. Pi?a, Emelia J. Benjamin, Megan J. Coylewright, Jorge F. Saucedo, Keith C. Ferdinand, Sharonne N. Hayes, Athena Poppas, Karen L. Furie, Laxmi S. Mehta, John P. Erwin III, Jennifer H. Mieres, Daniel J. Murphy Jr, Gaby Weissman, Colin P. West, Willie E. Lawrence Jr, Frederick A. Masoudi, Camara P. Jones, Daniel D. Matlock, Jennifer E. Miller, John A. Spertus, Lynn Todman, Cathleen Biga, Richard A. Chazal, Mark A. Creager, Edward T. Fry, Michael J. Mack, Clyde W. Yancy, Richard E. Anderson
doi : 10.1161/CIR.0000000000000963
Circulation. 2021;143:e1035–e1087
Evaluation and Management of Aortic Stenosis in Chronic Kidney Disease: A Scientific Statement From the American Heart Association
Gautam R. Shroff, Sripal Bangalore, Nicole M. Bhave, Tara I. Chang, Santiago Garcia, Roy O. Mathew, Janani Rangaswami, Julien Ternacle, Vinod H. Thourani, Philippe Pibarot, and on behalf of the American Heart Association Council on the Kidney in Cardiovascular Disease and Stroke Council
doi : 10.1161/CIR.0000000000000979
Circulation. 2021;143:e1088–e1114
Aortic stenosis with concomitant chronic kidney disease (CKD) represents a clinical challenge. Aortic stenosis is more prevalent and progresses more rapidly and unpredictably in CKD, and the presence of CKD is associated with worse short-term and long-term outcomes after aortic valve replacement. Because patients with advanced CKD and end-stage kidney disease have been excluded from randomized trials, clinicians need to make complex management decisions in this population that are based on retrospective and observational evidence. This statement summarizes the epidemiological and pathophysiological characteristics of aortic stenosis in the context of CKD, evaluates the nuances and prognostic information provided by noninvasive cardiovascular imaging with echocardiography and advanced imaging techniques, and outlines the special risks in this population. Furthermore, this statement provides a critical review of the existing literature pertaining to clinical outcomes of surgical versus transcatheter aortic valve replacement in this high-risk population to help guide clinical decision making in the choice of aortic valve replacement and specific prosthesis. Finally, this statement provides an approach to the perioperative management of these patients, with special attention to a multidisciplinary heart-kidney collaborative team-based approach.
Correction to: 2020 American Heart Association and American College of Cardiology Consensus Conference on Professionalism and Ethics: A Consensus Conference Report
doi : 10.1161/CIR.0000000000001002
Circulation. 2021;143:e1115
Correction to: Temporal Release of High-Sensitivity Cardiac Troponin T and I and Copeptin After Brief Induced Coronary Artery Balloon Occlusion in Humans
doi : 10.1161/CIR.0000000000000992
Circulation. 2021;143:e1116
Correction to: Cyclodextrin Prevents Abdominal Aortic Aneurysm via Activation of Vascular Smooth Muscle Cell Transcription Factor EB
doi : 10.1161/CIR.0000000000000993
Circulation. 2021;143:e1117
Correction to: A Randomized Trial of a 1-Hour Troponin T Protocol in Suspected Acute Coronary Syndromes: The Rapid Assessment of Possible Acute Coronary Syndrome in the Emergency Department With High-Sensitivity Troponin T Study (RAPID-TnT)
doi : 10.1161/CIR.0000000000000994
Circulation. 2021;143:e1118
